Evidence map›Paper›PMID 29566483›Full record

ArticleACS infectious diseases2018

Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.

Elena K Schneider-Futschik, Olivia K A Paulin, Daniel Hoyer, Kade D Roberts, James Ziogas, Mark A Baker, John Karas, Jian Li, Tony Velkov

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Antimicrobial Peptides against Multidrug-ResistantJournal of medicinal chemistry · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Elena K Schneider-FutschikDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia.ORCID 0000-0001-6044-4824
Olivia K A PaulinDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia.
Daniel HoyerDepartment of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences , The University of Melbourne , Parkville , Victoria 3010 , Australia.ORCID 0000-0002-1405-7089
Kade D RobertsMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia.
James ZiogasDepartment of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences , The University of Melbourne , Parkville , Victoria 3010 , Australia.
Mark A BakerPriority Research Centre in Reproductive Science, School of Environmental and Life Sciences , University of Newcastle , Callaghan , New South Wales 2308 , Australia.
John KarasDepartment of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences , The University of Melbourne , Parkville , Victoria 3010 , Australia.
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology , Monash University , Clayton , Victoria 3800 , Australia.
Tony VelkovDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia.ORCID 0000-0002-0017-7952
The University of Melbourne · AUMonash University · AUAustralian Regenerative Medicine Institute · AUScripps Research Institute · USUniversity of Newcastle Australia · AU

Funding

New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic CombinationsR01AI111965 · NIAID · MONASH UNIVERSITY · PI LI, JIAN · 2014 to 2018
$4.3M
Optimizing Dosing of Colistin for Infections Resistant to all Other AntibioticsR01AI070896 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SILVEIRA, FERNANDA P. · 2007 to 2011
$3.6M
Targeting MDR hetero-resistant Gram-negatives: PK/PD for rational combinationsR01AI079330 · NIAID · MONASH UNIVERSITY · PI NATION, ROGER L. · 2008 to 2011
$2.2M
NIAID NIH HHS R01 AI070896NIAID NIH HHS R01 AI079330NIAID NIH HHS R01 AI111965
6 · The paper itself

Abstract

The mucoid biofilm mode of growth of Pseudomonas aeruginosa ( P. aeruginosa) in the lungs of cystic fibrosis patients makes eradication of infections with antibiotic therapy very difficult. The lipopeptide antibiotics polymyxin B and colistin are currently the last-resort therapies for infections caused by multidrug-resistant P. aeruginosa. In the present study, we investigated the antibacterial activity of a series of polymyxin lipopeptides (polymyxin B, colistin, FADDI-003, octapeptin A

Indexed as

ActinsAnti-Bacterial AgentsBiofilmsCystic FibrosisDrug Resistance, Multiple, BacterialHumansLipopeptidesMicrobial Sensitivity TestsMucinsPolymyxin BProtein BindingPseudomonas aeruginosaSputumSurface-Active AgentsActinsAnti-Bacterial AgentsLipopeptidesMucinsPolymyxin BSurface-Active Agentsbiofilmcystic fibrosislipopeptidesmucoid “biofilm” growthnonmucoid “planktonic” growthP. aeruginosapolymyxinssputum

Identifiers

PMID29566483
PMCPMC5952261
OpenAlexW2793858051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.